Cryptocurrency payment adoption by compounding pharmacies — 2026

Dr.ObesityLA said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

I read this differently from Dr.ObesityLA, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

CryptoCarl said:

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Compounding pharmacy licensing verification for compounded supply: before ordering, verify your pharmacy's credentials:

1. State Board of Pharmacy license — check on your state BOP website
2. FDA registration (for 503B) — check on fda.gov
3. DEA registration if handling controlled substances
4. PCAB accreditation — voluntary but demonstrates commitment to quality
5. USP <797>/<800> compliance for sterile compounding

This takes 10 minutes of research and could save you from receiving substandard or unsafe medication.

DanielChem_CHI said:

A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.

Adding the part of the answer the thread has not reached. The trade-off is reversibility against privacy and there is no option that gives you both. Card payments are reversible and disclose the most; crypto discloses least and is irreversible, which is precisely why pressure toward it is a warning sign when it comes from a seller rather than a buyer. Escrow only means anything where the escrow agent is independent of both parties, which is rarely the case in practice.

One thing that is still open after Dr.SportsMedIN’s answer:

What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?

Closing the loop on my own question.

The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.